Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Regulatory Routine +

Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of (Pr)OKEDI(TM) (Risperidone for extended-release injectable suspension) for the treatment of schizophrenia

Canadian drug plan LOI for PrOKEDI is a steady commercial step, but the stock's -6.5% drift into the print reflects broader pipeline and debt overhangs already discounted.

By The Northwire Desk — AI Analysis Jun 09, 2026 · 08:00 BHC · 7.16 BAUSCH HEALTH COMPANIES INC.
Executive Summary
  • Bausch Health, Canada Inc. signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) to secure public drug plan coverage for PrOKEDI (risperidone extended-release injectable suspension) for schizophrenia.
  • The LOI follows positive Phase 3 PRISMA-3 trial data showing significant symptom improvement versus placebo and a 12-month extension confirming sustained disease stability.
  • Next steps involve finalizing Product Listing Agreements with federal, provincial, and territorial public drug plans to enable patient access.
  • This is a standard commercial/regulatory milestone for the Canadian pharmaceutical portfolio, not a transformative corporate event.
Material Impact
  • The PrOKEDI LOI is a positive commercial milestone for the Canadian portfolio but does not alter the company's fundamental debt profile, pipeline trajectory, or tariff exposure.
  • The stock had already declined -6.5% into the print, indicating that skepticism regarding the RED-C failure, tariff headwinds, and leverage was already discounted.
  • The news is Routine - Positive. It provides incremental commercial visibility but lacks the scale to re-rate the business or meaningfully impact the ~$2.65B market cap.
BHC · Price
Company Overview
  • Bausch Health is a diversified global pharmaceutical and healthcare company with segments in gastroenterology (Salix), aesthetics (Solta Medical), eye health (Bausch + Lomb), international pharma, and diversified products.
  • Strategic focus includes debt reduction, pipeline development (Larsucosterol for alcohol-associated hepatitis), and geographic expansion in China via the Shibo acquisition.
  • The company is navigating a complex transition from legacy litigation settlements to a leaner, debt-focused operating model while preparing for Xifaxan loss-of-exclusivity in 2028.
Read the original news release →

More from BAUSCH HEALTH COMPANIES INC.

May 28, 2026 · 16:15

Solta Trademark Win Reinforces China Growth Narrative Amidst Elevated Debt Costs and Xifaxan LOE Clock

Production / Operations Apr 29, 2026 · 16:05

BHC Q1 Earnings Mask Pipeline Failure with Core Cash Flow Strength

Earnings Apr 14, 2026 · 08:00

Biafine Launch Fails to Offset Clinical Failure and Debt Burden

Other Feb 23, 2026 · 17:59

Bausch Health launches Clear + Brilliant in Canada

Regulatory Feb 23, 2026 · 08:00

Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant(TM) Touch Laser in Canada

Production / Operations Feb 18, 2026 · 16:05

BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

Earnings